San Diego-based Viking Therapeutics marked alone as a significant competitor during the weight loss drug marketplace in February after revealing promising info from the mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when offered for a weekly injection and in March the company unveiled